RSM 容诚 内部控制审计报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行了新 您可 内部控制审计报告 容诚审字[2025]100Z1525 5 无锡祥生医疗科技股份有限公司全体股东: 无锡祥生医疗科技股份有限公司 容诚审字|2025]100Z1525 号 容诚会计师事务所(特 骑 缝 容诚会计师事务所(特殊普通合伙) 中国 北京 我们认为,祥生医疗公司于 2024年12月 31 日按照《企业内部控制基本规范》 和相关规定在所有重大方面保持了有效的财务报告内部控制。 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了无锡祥生医疗科技股份有限公司(以下简称"祥生医疗公司")2024年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是祥生 医疗公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见,并对注 ...

审计报告 无锡祥生医疗科技股份有限公司 容诚审字[2025]100Z1524 号 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 审 计 报 告 容诚审字[2025]100Z1524 号 无锡祥生医疗科技股份有限公司全体股东： 关键审计事项是我们根据职业判断，认为对2024年度财务报表审计最为重要 的事项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背景，我 们不对这些事项单独发表意见。 （一）外销产品收入确认 1 1、事项描述 参见财务报表附注三.26 收入确认原则和计量方法、附注五.33 营业收入和营 业成本。 祥生医疗公司 2024 年营业总收入为人民币 46,869.72 万元，其中外销产品收 入占比为 86.47%。由于外销产品收入占比较高，对祥生医疗公司财务报表具有 ...

国金证券股份有限公司（以下简称"保荐机构"）作为无锡祥生医疗科技股份有限公 司（以下简称"祥生医疗"或"公司"）持续督导工作的保荐机构，根据《证券发行上市保 荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管指引 第 11 号——持续督导》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等有关规定，对祥生医疗 2024 年度募集资金存放与使用情况进行了审慎核查， 并发表核查意见如下： 一、首次公开发行股票募集资金的基本情况 （一）实际募集资金金额和资金到账时间 国金证券股份有限公司 关于无锡祥生医疗科技股份有限公司 2024 年度募集资金存放与使用情况的核查意见 （二）本年度募集资金使用金额及年末余额 经中国证券监督管理委员会《关于同意无锡祥生医疗科技股份有限公司首次公开发 行股票注册的批复》（证监许可[2019]2018 号）核准，公司于 2019 年 11 月向社会公开 发行人民币普通股（A 股）2,000.00 万股，每股发行价为 50.53 元，应募集资金总额为 人民币 101 ...

无锡祥生医疗科技股份有限公司 2024 年度独立董事述职报告 本人宋安成作为无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公 司"）第三届董事会独立董事，根据《公司法》《证券法》《无锡祥生医疗科技股份 有限公司章程》《无锡祥生医疗科技股份有限公司独立董事工作制度》《无锡祥生 医疗科技股份有限公司独立董事专门会议工作制度》及有关法律、法规的规定, 忠 实履行职责，认真审议各项议案，积极出席相关会议，了解宏观经济形势和企业运 营状况，客观、独立、负责地参与公司决策，维护公司整体利益及全体股东特别是 中小股东的合法权益，自觉促进和维护董事会规范有效运作，为推动公司加快发展 建言献策。现将2024年度履职情况报告如下: 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 宋安成，男，1975年出生，中国国籍，无境外永久居留权，毕业于辽宁大学法 律专业，获硕士学位。2006年6月至2009年1月，就职于上海市建纬律师事务所任律 师；2009年1月至2010年10月，就职于上海恒隆律师事务所任合伙人；2010年10月至 2019年5月，就职于北京盈科（上海）律师事务所任高级合伙人；2019年5月至今 ...

4月24日祥生医疗发布2024年度分配预案，拟10派10元（含税），预计派现金额合计为1.12亿元。派现 额占净利润比例为79.62%，以该股2024年度成交均价计算，股息率为3.59%。这是公司上市以来，累计 第6次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2024.12.31 | 10派10元（含税） | 1.12 | 3.59 | | 2023.12.31 | 10派8元（含税） | 0.89 | 1.78 | | 2022.12.31 | 10派7元（含税） | 0.78 | 1.82 | | 2021.12.31 | 10转增4派5元（含税） | 0.40 | 1.03 | | 2020.12.31 | 10派8元（含税） | 0.64 | 1.14 | | 2019.12.31 | 10派10元（含税） | 0.80 | 2.08 | 证券时报·数据宝统计显示，公司今日公布了2024年报，共实现营业收入4.69亿元，同比下降3.13%，实 现净利润1.41亿元，同比下降4.0 ...

Financial Performance - Revenue for Q1 2025 was CNY 127.71 million, a decrease of 9.16% compared to CNY 140.60 million in the same period last year[4] - Net profit attributable to shareholders was CNY 41.61 million, down 8.62% from CNY 45.54 million year-on-year[4] - Basic and diluted earnings per share were both CNY 0.37, reflecting a decline of 9.76% from CNY 0.41 in the previous year[5] - Operating profit for Q1 2025 was ¥47.20 million, a decline of 9.3% compared to ¥52.41 million in Q1 2024[20] - Net profit for Q1 2025 was ¥41.61 million, down 8.5% from ¥45.54 million in Q1 2024[20] Cash Flow and Liquidity - Net cash flow from operating activities decreased by 20.14% to CNY 21.04 million, compared to CNY 26.34 million in the same period last year[5] - Cash flow from operating activities for Q1 2025 was ¥21.04 million, down 20.3% from ¥26.34 million in Q1 2024[24] - Cash and cash equivalents at the end of Q1 2025 increased to ¥847.61 million from ¥239.77 million at the end of Q1 2024[25] - The company's cash and cash equivalents increased to RMB 1,016,854,712.62 from RMB 985,616,661.93, representing a rise of about 3.2%[15] Assets and Liabilities - Total assets increased by 1.56% to CNY 1,621.89 million from CNY 1,597.01 million at the end of the previous year[4] - The company's total liabilities decreased to RMB 159,670,323.30 from RMB 176,423,213.57, a decline of about 9.5%[17] - Total current liabilities decreased to RMB 149,367,227.11 from RMB 166,785,376.57, a reduction of approximately 10.5%[16] - The company's total equity increased to RMB 1,462,219,998.56 from RMB 1,420,586,554.05, reflecting a growth of about 2.8%[17] Research and Development - R&D expenses totaled CNY 17.46 million, representing 13.67% of revenue, a slight decrease from 13.74% in the previous year[5] - Research and development expenses for Q1 2025 were ¥17.46 million, a decrease of 11.2% from ¥19.66 million in Q1 2024[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,509[10] - The largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 40.46% of the shares, totaling 45,360,000 shares[11] Other Financial Metrics - Financial expenses increased by 36.10%, primarily due to exchange rate fluctuations leading to increased foreign exchange losses[8] - The company reported non-recurring gains of CNY 2.74 million for the period[7] - The company reported a decrease in other comprehensive income, with a net loss of ¥518.53 thousand in Q1 2025 compared to a gain of ¥5.60 thousand in Q1 2024[20] - Accounts receivable rose to RMB 182,887,395.62, up from RMB 161,693,930.83, indicating an increase of approximately 13.1%[15] - Inventory decreased to RMB 107,496,307.15 from RMB 126,328,601.45, showing a decline of about 14.9%[15] - The non-current assets totaled RMB 195,821,486.94, slightly up from RMB 191,975,337.83, indicating a growth of approximately 2.0%[16] - The company's retained earnings increased to RMB 398,597,640.81 from RMB 356,983,110.49, representing a growth of approximately 11.6%[17] - The company experienced a net cash inflow from investment activities of ¥9.50 million in Q1 2025, slightly up from ¥9.44 million in Q1 2024[25]

Dividend Distribution - The company plans to distribute a cash dividend of 10 RMB per 10 shares, totaling approximately 111.87 million RMB, which represents 79.62% of the net profit attributable to shareholders for the year[5]. - The profit distribution plan has been approved by the board and will be submitted for shareholder approval at the 2024 annual general meeting[6]. - The total number of employees in the parent company and major subsidiaries is 537, with 186 in technical roles and 124 in sales[164]. - The cumulative cash dividend over the last three accounting years amounts to 279,861,731.30 RMB, with an average net profit of 130,942,887.15 RMB, resulting in a cash dividend ratio of 213.73%[178]. - The company has a cash dividend policy that prioritizes stable returns to shareholders while considering long-term growth and major investment plans[171]. Financial Performance - The company reported a revenue increase of 15% in 2024 compared to 2023, reaching a total of 500 million RMB[22]. - The company's operating revenue for 2024 was approximately ¥468.70 million, a decrease of 3.13% compared to ¥483.84 million in 2023[24]. - Net profit attributable to shareholders was approximately ¥140.51 million, down 4.08% from ¥146.48 million in the previous year[24]. - The net cash flow from operating activities increased significantly by 63.76% to approximately ¥140.68 million, compared to ¥85.91 million in 2023[24]. - The company's total assets reached approximately ¥1.60 billion, reflecting a growth of 4.89% from ¥1.52 billion at the end of 2023[24]. Research and Development - Research and development expenses increased by 10% in 2024, reflecting the company's commitment to innovation and new technology[22]. - The R&D investment as a percentage of operating revenue increased to 16.99%, up from 15.93% in the previous year[25]. - The company invested CNY 79.63 million in R&D, accounting for 16.99% of its revenue, and received 48 new patent authorizations, including 30 invention patents[34]. - The company has accumulated a total of 61 core technologies, focusing on continuous R&D investment to drive innovation in ultrasound medical imaging equipment[76]. - The company has introduced 10 new core technologies during the reporting period, enhancing portable ultrasound and AI ultrasound capabilities[75]. Market Position and Strategy - The company achieved a market share of 15% in the domestic ultrasound device market, positioning itself as a key player[22]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the medical imaging sector[22]. - The company aims to become a global leader in specialized ultrasound by focusing on high-end color ultrasound, portable devices, and AI integration[133]. - The company has established a nationwide sales network covering over 30 provinces and regions in China, with significant growth potential in the domestic market due to its differentiated technology and international quality standards[63]. - The company is actively involved in the development of AI-assisted diagnostic technologies, enhancing the capabilities of its medical imaging devices[65]. Corporate Governance - The company has established a governance structure that ensures independence and coordination among the shareholders' meeting, board of directors, and management[141]. - The company has not reported any issues regarding independence or operational capability concerning its controlling shareholders[141]. - The board of directors includes members with extensive experience, such as the chairman and general manager, who has held the position since August 2023[145]. - The company has maintained a stable shareholding structure, with no changes in the number of shares held by directors during the reporting period[145]. - The company has established a remuneration and assessment committee to draft remuneration proposals for senior management[153]. Risk Management - The company has provided a detailed risk analysis regarding potential operational risks in the report[3]. - The company is facing risks related to product development failures due to the complexity of ultrasound technology[89]. - There is a risk of technology leakage that could negatively impact the company's competitive advantage[91]. - The company has not reported any significant risk issues reported by the supervisory board during the reporting period[163]. - The company has established a unified management process for subsidiaries to enhance operational efficiency and risk management[190]. Social Responsibility and ESG - The company emphasizes the importance of ESG practices, integrating sustainable development into daily operations and strategic decisions[193]. - The company actively participates in social responsibility initiatives, including medical assistance programs[192]. - The company has received ESG ratings of BB from Wind and Huazheng, and BBB from Zhidin[198]. - The company integrates green energy-saving design concepts into its product development, aiming to reduce energy costs and carbon emissions[197]. - The company has implemented strict waste classification, storage, and processing procedures to enhance recycling rates and reduce secondary pollution[197].

无锡祥生医疗科技股份有限公司 董事会审计委员会 对 2024 年会计师事务所履行监督职责情况报告 无锡祥生医疗科技股份有限公司（以下简称"祥生医疗"或"公司"）聘请容诚 会计师事务所（特殊普通合伙）（以下简称"容诚"）作为公司 2024 年度境内财务 报告审计机构和内部控制审计机构。 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通 合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证 券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26，首席合伙人刘维。 截至 2024 年 12 月 31 日，容诚会计师事务所共有合伙人 212 人，共有注册 会计师 1552 人，其中 781 人签署过证券服务业务审计报告。 （二）聘任会计师事务所履行的程序 公司于 2024 年 4 月 18 日召开的第三届董事会独立董事专门会议第一次会议、 第三届董事会审计委员会第三次会议、第三届董事会第五次会议、第三届监事会 第五次会议审议通过了《 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2025-009 无锡祥生医疗科技股份有限公司 关于开展外汇套期保值业务的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司拟开展的外汇套期保值业务资金额度折合不超过8000万美元（含本 数）或其他等值外币（额度范围内资金可滚动使用），资金来源为自有资金。额 度有效期为自公司2024年年度股东大会审议通过之日起12个月。 公司的外汇套期保值业务以正常生产经营为基础，以规避和防范汇率风 险为目的，不进行单纯以盈利为目的的投机和套利交易。 本事项尚需提交公司2024年年度股东大会审议。 无锡祥生医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第三届董事会第十二次会议和第三届监事会第十一次会议，审议通过了 《关于开展外汇套期保值业务的议案》，同意公司为规避外汇市场风险，使用自 有资金与银行开展外汇套期保值业务。该议案尚需提交公司 2024 年年度股东大 会审议。现将具体情况公告如下： 一、开展外汇套期保值业务的必要性 公司出 ...

报告期内，公司董事会审计委员会共召开会议 3 次，全体委员均亲自出席，具 体情况如下： 无锡祥生医疗科技股份有限公司 2024 年度董事会审计委员会工作报告 根据中国证监会《上市公司治理准则》《上海证券交易所科创板股票上市规则》 和《无锡祥生医疗科技股份有限公司章程》《无锡祥生医疗科技股份有限公司董事会 审计委员会工作细则》等有关规定，无锡祥生医疗科技股份有限公司（以下简称"祥 生医疗"或"公司"）董事会审计委员会本着勤勉尽责的原则，认真履行了审计监督 职责。现将公司审计委员会 2024 年度工作情况报告如下： 一、审计委员会基本情况 第三届董事会审计委员会共有 3 名委员：李寿喜先生（主任委员）、宋安成先生、 莫善珏先生。其中主任委员具有专业财会知识。 二、审计委员会召开会议情况 | 时间 | | 届次 1. | 审议事项 《关于 2023 年年度报告正文及其摘要中财务数 | | --- | --- | --- | --- | | | | 2. | 据的议案》 《关于聘请 2024 年度审计机构的议案》 | | | | 3. | 《关于 2023 年度利润分配方案的议案》 | | | | 第三届董事会 4. ...